|  |
| --- |
| **Supplemental Digital Content.** Methodological index for nonrandomized studies (MINORS) scores of the included studies |
| **Study** | **Clearly stated aim** | **Inclusion of consecutive patients** | **Prospective collection of data** | **Endpoints appropriate to aim of study** | **Unbiased assessment of study endpoint** | **Follow-up period appropriate to aim of study** | **Loss to follow-up of less than 5%** | **Prospective calculation of sample size**  | **Adequate control group** | **Contemporary groups** | **Baseline equivalence of groups** | **Adequate statistical analyses** | **Total** |
| Ding et al20 | 2 | 2 | 0 | 2 | 0 | 1 | 1 | 0 | 2 | 2 | 1 | 2 | 15/24 |
| Hupel et al24 | 2 | 0 | 1 | 2 | 0 | 2 | 1 | 0 | 2 | 2 | 1 | 2 | 15/24 |
| Iqbal et al12 | 2 | 2 | 0 | 2 | 0 | 2 | 2 | 0 | 2 | 2 | 1 | 2 | 17/24 |
| Jaeblon et al13 | 2 | 2 | 0 | 2 | 1 | 1 | 0 | 0 | 2 | 2 | 2 | 2 | 16/24 |
| Karunakar et al14 | 2 | 2 | 0 | 2 | 0 | 2 | 1 | 0 | 2 | 2 | 1 | 2 | 16/24 |
| Li et al15  | 2 | 2 | 0 | 2 | 0 | 0 | 0 | 0 | 2 | 2 | 1 | 2 | 13/24 |
| Mears et al23 | 1 | 2 | 0 | 2 | 0 | 2 | 1 | 0 | N/A | N/A | N/A | N/A | 8/16 |
| Mourad et al25 | 2 | 2 | 0 | 2 | 0 | 2 | 1 | 0 | 2 | 2 | 1 | 2 | 16/24 |
| Porter et al16 | 2 | 2 | 1 | 2 | 0 | 2 | 0 | 0 | 1 | 2 | 1 | 2 | 15/24 |
| Porter et al26 | 2 | 2 | 1 | 2 | 0 | 2 | 0 | 0 | 1 | 2 | 1 | 2 | 15/24 |
| Sagi et al17 | 2 | 1 | 0 | 2 | 0 | 1 | 0 | 0 | 2 | 2 | 2 | 2 | 14/24 |
| Sems et al18 | 2 | 2 | 0 | 2 | 0 | 2 | 2 | 0 | 2 | 2 | 1 | 2 | 17/24 |
| Shaath et al22 | 2 | 2 | 0 | 2 | 2 | 0 | 0 | 0 | 2 | 2 | 1 | 2 | 15/24 |
| Suzuki et al19 | 2 | 1 | 0 | 2 | 0 | 0 | 0 | 0 | 2 | 2 | 1 | 2 | 12/24 |
| Vincent et al21 | 2 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 2 | 2 | 1 | 2 | 11/24 |

Subsection scores: 2 = reported and adequate, 1 = reported but inadequate, 0 = not reported